1	YU YC, MAO YM, CHEN CW, et al. CSH guidelines for the diagnosis and treatment of drug-induced liver injury[J]. Hepatol Int, 2017, 11(3): 221-241. DOI: 10.1007/s12072-017-9793-2 . 本文引用 [1]

2	BJÖRNSSON ES, BERGMANN OM, BJÖRNSSON HK, et al. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland[J]. Gastroenterology, 2013, 144(7): 1419-1425. DOI: 10.1053/j.gastro.2013.02.006 . 本文引用 [1]

3	SGRO C, CLINARD F, OUAZIR K, et al. Incidence of drug-induced hepatic injuries: A French population-based study[J]. Hepatology, 2002, 36(2): 451-455. DOI: 10.1053/jhep.2002.34857 .

4	SHEN T, LIU YX, SHANG J, et al. Incidence and etiology of drug-induced liver injury in mainland China[J]. Gastroenterology, 2019, 156(8): 2230-2241. e11. DOI: 10.1053/j.gastro.2019.02.002 . 本文引用 [1]

5	CHALASANI N, BONKOVSKY HL, FONTANA R, et al. Features and outcomes of 899 patients with drug-induced liver injury: The DILIN prospective study[J]. Gastroenterology, 2015, 148(7): 1340-1352. e7. DOI: 10.1053/j.gastro.2015.03.006 . 本文引用 [3]

6	LICATA A, MINISSALE MG, CALVARUSO V, et al. A focus on epidemiology of drug-induced liver injury: Analysis of a prospective cohort[J]. Eur Rev Med Pharmacol Sci, 2017, 21(1 ): 112-121. 摘要 Suppl

7	CHALASANI N, FONTANA RJ, BONKOVSKY HL, et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States[J]. Gastroenterology, 2008, 135(6): 1924-1934. e1-e4. DOI: 10.1053/j.gastro.2008.09.011 . 本文引用 [1]

8	BJORNSSON ES, JONASSON JG. Drug-induced cholestasis[J]. Clin Liver Dis, 2013, 17(2): 191-209. DOI: 10.1016/j.cld.2012.11.002 . 本文引用 [1]

9	LAMMERT C, IMLER T, TEAL E, et al. Patients with chronic liver disease suggestive of nonalcoholic fatty liver disease may be at higher risk for drug-induced liver injury[J]. Clin Gastroenterol Hepatol, 2019, 17(13): 2814-2815. DOI: 10.1016/j.cgh.2018.12.013 . 本文引用 [1]

10	BESSONE F, DIRCHWOLF M, RODIL MA, et al. Review article: Drug-induced liver injury in the context of nonalcoholic fatty liver disease-a physiopathological and clinical integrated view[J]. Aliment Pharmacol Ther, 2018, 48(9): 892-913. DOI: 10.1111/apt.14952 . 本文引用 [1]

11	CHALASANI N, ALJADHEY H, KESTERSON J, et al. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity[J]. Gastroenterology, 2004, 126(5): 1287-1292. DOI: 10.1053/j.gastro.2004.02.015 . 本文引用 [1]

12	RUSSO MW, HOOFNAGLE JH, GU JZ, et al. Spectrum of statin hepatotoxicity: Experience of the drug-induced liver injury network[J]. Hepatology, 2014, 60(2): 679-686. DOI: 10.1002/hep.27157 . 本文引用 [1]

13	WATKINS PB, SELIGMAN PJ, PEARS JS, et al. Using controlled clinical trials to learn more about acute drug-induced liver injury[J]. Hepatology, 2008, 48(5): 1680-1689. DOI: 10.1002/hep.22633 . 本文引用 [1]

14	FONTANA RJ, HAYASHI PH, BARNHART H, et al. Persistent liver biochemistry abnormalities are more common in older patients and those with cholestatic drug induced liver injury[J]. Am J Gastroenterol, 2015, 110(10): 1450-1459. DOI: 10.1038/ajg.2015.283 . 本文引用 [1]

15	BJÖRNSSON E, DAVIDSDOTTIR L. The long-term follow-up after idiosyncratic drug-induced liver injury with jaundice[J]. J Hepatol, 2009, 50(3): 511-517. DOI: 10.1016/j.jhep.2008.10.021 . 本文引用 [1]

16	YOKODA RT, RODRIGUEZ EA. Review: Pathogenesis of cholestatic liver diseases[J]. World J Hepatol, 2020, 12(8): 423-435. DOI: 10.4254/wjh.v12.i8.423 . 本文引用 [1]

17	Chinese Society of Hepatology, Chinese Medical Association. Guideline on the management of cholestasis liver diseases[J]. J Clin Hepatol, 2022, 38(1): 62-69. 中华医学会肝病学分会. 胆汁淤积性肝病管理指南(2021年)[J]. 临床肝胆病杂志, 2022, 38(1): 62-69. 本文引用 [2]

18	GOSSARD AA, TALWALKAR JA. Cholestatic liver disease[J]. Med Clin North Am, 2014, 98(1): 73-85. DOI: 10.1016/j.mcna.2013.09.002 . 本文引用 [1]

19	SARCOGNATO S, SACCHI D, GRILLO F, et al. Autoimmune biliary diseases: Primary biliary cholangitis and primary sclerosing cholangitis[J]. Pathologica, 2021, 113(3): 170-184. DOI: 10.32074/1591-951X-245 . 本文引用 [1]

20	PINZANI M, LUONG TV. Pathogenesis of biliary fibrosis[J]. Biochim Biophys Acta Mol Basis Dis, 2018, 1864(4 Pt B): 1279-1283. DOI: 10.1016/j.bbadis.2017.07.026 .

21	JANSEN PLM, GHALLAB A, VARTAK N, et al. The ascending pathophysiology of cholestatic liver disease[J]. Hepatology, 2017, 65(2): 722-738. DOI: 10.1002/hep.28965 . 本文引用 [1]

22	CHALASANI NP, MADDUR H, RUSSO MW, et al. ACG clinical guideline: Diagnosis and management of idiosyncratic drug-induced liver injury[J]. Am J Gastroenterol, 2021, 116(5): 878-898. DOI: 10.14309/ajg.0000000000001259 . 本文引用 [3]

23	BJÖRNSSON HK, BJÖRNSSON ES. Drug-induced liver injury: Pathogenesis, epidemiology, clinical features, and practical management[J]. Eur J Intern Med, 2022, 97: 26-31. DOI: 10.1016/j.ejim.2021.10.035 . 本文引用 [1]

24	NORMAN BH. Drug induced liver injury (DILI). Mechanisms and medicinal chemistry avoidance/mitigation strategies[J]. J Med Chem, 2020, 63(20): 11397-11419. DOI: 10.1021/acs.jmedchem.0c00524 . 本文引用 [1]

25	LARREY D, ERLINGER S. Drug-induced cholestasis[J]. Baillieres Clin Gastroenterol, 1988, 2(2): 423-452. DOI: 10.1016/0950-3528(88)90010-3 . 本文引用 [1]

26	BESSONE F, HILLOTTE GL, AHUMADA N, et al. UDCA for drug-induced liver disease: Clinical and pathophysiological basis[J]. Semin Liver Dis, 2024, 44(1): 1-22. DOI: 10.1055/s-0044-1779520 . 本文引用 [1]

27	HU PF, WANG PQ, CHEN H, et al. Beneficial effect of corticosteroids for patients with severe drug-induced liver injury[J]. J Dig Dis, 2016, 17(9): 618-627. DOI: 10.1111/1751-2980.12383 . 本文引用 [1]

28	HIRSCHFIELD GM, DYSON JK, ALEXANDER GJM, et al. The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines[J]. Gut, 2018, 67(9): 1568-1594. DOI: 10.1136/gutjnl-2017-315259 . 本文引用 [2]

29	FLOREANI A, de MARTIN S. Treatment of primary sclerosing cholangitis[J]. Dig Liver Dis, 2021, 53(12): 1531-1538. DOI: 10.1016/j.dld.2021.04.028 . 本文引用 [2]

30	ASCHENBRENNER DS. Excessive dosing of obeticholic acid may increase risk of liver damage[J]. Am J Nurs, 2018, 118(2): 46. DOI: 10.1097/01.NAJ.0000530245.53335.c8 . 本文引用 [1]

31	U.S. Food and Drug Administration (FDA). FDA drug safety communication: FDA warns about serious liver injury with ocaliva (obeticholic acid) for rare chronic liver disease[EB/OL]. [2024-05-30]. https://www.fda.gov/media/104801/download 本文引用 [1]

32	U.S. National Institutes of Health (NIH). LiverTox: Clinical and research information on drug-induced liver injury[EB/OL]. [2024-05-30]. https://livertox.nlm.nih.gov 本文引用 [1]

33	HIRSCHFIELD GM, MASON A, LUKETIC V, et al. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid[J]. Gastroenterology, 2015, 148(4): 751-761. e8. DOI: 10.1053/j.gastro.2014.12.005 . 本文引用 [2]

34	KOWDLEY KV, LUKETIC V, CHAPMAN R, et al. A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis[J]. Hepatology, 2018, 67(5): 1890-1902. DOI: 10.1002/hep.29569 .

35	NEVENS F, ANDREONE P, MAZZELLA G, et al. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis[J]. N Engl J Med, 2016, 375(7): 631-643. DOI: 10.1056/NEJMoa1509840 . 本文引用 [1]

36	QUIGLEY G, AL ANI M, NADIR A. Occurrence of jaundice following simultaneous ursodeoxycholic acid cessation and obeticholic acid initiation[J]. Dig Dis Sci, 2018, 63(2): 529-532. DOI: 10.1007/s10620-017-4900-8 . 本文引用 [1]

37	HASEGAWA S, YONEDA M, KURITA Y, et al. Cholestatic liver disease: Current treatment strategies and new therapeutic agents[J]. Drugs, 2021, 81(10): 1181-1192. DOI: 10.1007/s40265-021-01545-7 . 本文引用 [1]

38	ZHANG JP. Pathological diagnosis of cholestatic liver disease[J]. J Clin Hepatol, 2024, 40(6): 1093-1099. DOI: 10.12449/JCH240605 . 张继平. 胆汁淤积性肝病的病理学诊断[J]. 临床肝胆病杂志, 2024, 40(6): 1093-1099. DOI: 10.12449/JCH240605 .

39

BAI HH, FENG HJ, GUO LJ, et al. An analysis on the clinical biochemical and pathological characteristics of simple cholestatic type of drug induced liver injury[J]. Chin Hepatol, 2024, 29(1): 37-40, 55. DOI: 10.14000/j.cnki.issn.1008-1704.2024.01.011 . 白欢欢, 冯惠君, 郭立杰, 等. 单纯淤胆型药物性肝损伤临床生化及病理特点分析[J]. 肝脏, 2024, 29(1): 37-40, 55. DOI: 10.14000/j.cnki.issn.1008-1704.2024.01.011 .

40	ALLISON R, GURAKA A, SHAWA IT, et al. Drug induced liver injury-a 2023 update[J]. J Toxicol Environ Health B Crit Rev, 2023, 26(8): 442-467. DOI: 10.1080/10937404.2023.2261848 . 本文引用 [1]

41	WEILER S, MERZ M, KULLAK-UBLICK GA. Drug-induced liver injury: The dawn of biomarkers?[J]. F1000Prime Rep, 2015, 7: 34. DOI: 10.12703/P7-34 . 本文引用 [1]

42	KWO PY, COHEN SM, LIM JK. ACG clinical guideline: Evaluation of abnormal liver chemistries[J]. Am J Gastroenterol, 2017, 112(1): 18-35. DOI: 10.1038/ajg.2016.517 . 本文引用 [1]

43	BJÖRNSSON E, TALWALKAR J, TREEPRASERTSUK S, et al. Drug-induced autoimmune hepatitis: Clinical characteristics and prognosis[J]. Hepatology, 2010, 51(6): 2040-2048. DOI: 10.1002/hep.23588 . 本文引用 [1]

44	DELEMOS AS, FOUREAU DM, JACOBS C, et al. Drug-induced liver injury with autoimmune features[J]. Semin Liver Dis, 2014, 34(2): 194-204. DOI: 10.1055/s-0034-1375959 . 本文引用 [1]

45	SUZUKI A, BRUNT EM, KLEINER DE, et al. The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury[J]. Hepatology, 2011, 54(3): 931-939. DOI: 10.1002/hep.24481 . 本文引用 [1]

46	BÉNICHOU C. Criteria of drug-induced liver disorders. Report of an international consensus meeting[J]. J Hepatol, 1990, 11(2): 272-276. DOI: 10.1016/0168-8278(90)90124-a . 本文引用 [1]

47	YOUNOSSI ZM, BERNSTEIN D, SHIFFMAN ML, et al. Diagnosis and management of primary biliary cholangitis[J]. Am J Gastroenterol, 2019, 114(1): 48-63. DOI: 10.1038/s41395-018-0390-3 . 本文引用 [1]

48	FEJFAR T, VAŇÁSEK T, HŮLEK P. Chronic cholestatic liver diseases-Primary biliary cholangitis and Primary sclerosing cholangitis[J]. Vnitr Lek, 2020, 66(5): 287-300.

49	BLUM HE. Chronic cholestatic liver diseases[J]. J Gastroenterol Hepatol, 2002, 17 (): S399-S402. DOI: 10.1046/j.1440-1746.17.s3.34.x . 本文引用 [1] 摘要 Suppl 3

50	PADDA MS, SANCHEZ M, AKHTAR AJ, et al. Drug-induced cholestasis[J]. Hepatology, 2011, 53(4): 1377-1387. DOI: 10.1002/hep.24229 . 本文引用 [1]

51	TRIVEDI PJ, HIRSCHFIELD GM. Recent advances in clinical practice: Epidemiology of autoimmune liver diseases[J]. Gut, 2021, 70(10): 1989-2003. DOI: 10.1136/gutjnl-2020-322362 . 本文引用 [1]

52	LI XY, TANG JT, MAO YM. Incidence and risk factors of drug-induced liver injury[J]. Liver Int, 2022, 42(9): 1999-2014. DOI: 10.1111/liv.15262 . 本文引用 [1]